Grants and Contracts Details
| Status | Finished |
|---|---|
| Effective start/end date | 1/9/23 → 11/30/24 |
Funding
- Kinnate Biopharma Incorporated: $27,721.00
22-MULTI-53-KB-PMC : A Phase 1/1b Open-label, Multicenter Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of KIN-2787 in Participants with BRAF and/or NRAS Mutation-positive Solid Tumors, KN-8701
- Arnold, Susanne (PI)